Millennium commences Phase 3 trial of MLN9708
The TOURMALINE-MM1 study will compare oral MLN9708 plus lenalidomide and dexamethasone to placebo plus lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma. The randomized, double-blind,